[Ophtalmological adverse events related to immune checkpoint inhibitors].

Immune checkpoint inhibitors are now an integral part of the anti-cancer therapeutic arsenal. They have revolutionized the prognosis of certain cancers at the cost of a specific spectrum of dysimmune side effects that can affect the ophthalmological sphere. Patient education associated with increased vigilance of health care providers will allow faster detection and therefore optimal care to limit morbidity, maintain the best possible visual acuity and above all to be able to continue therapy prolonging survival. In this article, we describe the main ocular side effects as well as an outline of their management.